Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Aggressive cholesterol drugs may shrink artery plaque in young patients

NCT ID NCT05783804

First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 33 times

Summary

This study tests whether starting strong cholesterol-lowering therapy early can reverse plaque buildup in the arteries of young adults (ages 18-50) with familial hypercholesterolemia, a genetic condition causing very high cholesterol. Researchers will use CT scans to measure changes in plaque volume over time. The goal is to see if aggressive treatment can stop or even reverse artery disease progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE PROGRESSION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Amsterdam UMC, location AMC

    RECRUITING

    Amsterdam, North Holland, 1105 AZ, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

lipid-lowering therapy (statins and/or other cholesterol drugs)

What this could lead to

If it works, this could show that early aggressive treatment can reverse artery plaque buildup, potentially reducing heart attack risk in young people with this genetic condition.

What could go wrong

This is a small early-phase study with only 60 participants, so results may not apply to everyone. Plaque reversal may be modest or not occur, and aggressive lipid-lowering carries risks like muscle pain or liver issues.

Conditions

The condition(s) this trial relates to.

coronary artery disorder familial hypercholesterolemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.